CSIMarket
 


Allogene Therapeutics inc   (ALLO)
Other Ticker:  
 

Cumulative Allogene Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

ALLO's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ALLO Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -30.99 % -22.99 % 21.85 % 61.58 % 11.53 %
Y / Y Cash & cash equivalent Growth -13.27 % -15.7 % 0.3 % 4.94 % 13.12 %
Quick Ratio for Trailing Twelve Months Period 9.93 9.46 9.37 9.81 10.9
Total Ranking # 279 # 321 # 430 # 454 # 434
Seq. Current Liabilities Growth -1.48 % -31.22 % -8.16 % 10.9 % 9.94 %
Seq. Cash & cash equivalent Growth -3.61 % -5.38 % 4.4 % -8.91 % -6.32 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Current Liabilities decreased faster than Allogene Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Allogene Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period to 9.93, Quick Ratio for Trailing Twelve Months Period remained below Allogene Therapeutics inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Allogene Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about ALLO
Quick Ratio ALLO in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 32
Sector # 154
S&P 500 # 229


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
18.31 11.79 4.32
(Sep 30 2020)   (Mar 31 2019)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Vigil Neuroscience Inc   24.89 
Apogee Therapeutics inc   24.62 
Intensity Therapeutics Inc   21.61 
Tourmaline Bio Inc   20.06 
Vor Biopharma Inc   19.78 
Cullinan Oncology Inc   19.59 
Pharmacyte Biotech Inc   19.40 
Genenta Science S p a   19.32 
Graphite Bio Inc   19.20 
Cortexyme Inc   17.86 
Neumora Therapeutics Inc   17.50 
Aura Biosciences Inc   17.36 
Hillevax Inc   16.86 
4d Molecular Therapeutics Inc   16.24 
Icosavax Inc   16.22 
Revolution Medicines Inc   16.19 
Acumen Pharmaceuticals Inc   15.95 
Replimune Group Inc   15.59 
Compass Therapeutics Inc   15.31 
Fusion Pharmaceuticals Inc   15.21 
Krystal Biotech Inc   14.64 
Crispr Therapeutics Ag  14.34 
Ikena Oncology Inc   13.92 
Invivyd Inc   13.42 
Voyager Therapeutics Inc   13.17 
Kymera Therapeutics Inc   13.01 
Protara Therapeutics Inc   12.95 
Achilles Therapeutics Plc  12.56 
Cabaletta Bio Inc   12.40 
Cardiff Oncology inc   12.37 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com